- Home
- SMG vs KNSA Comparison
SMG vs KNSA Comparison
Compare SMG & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SMG | KNSA |
|---|---|---|
| Founded | 1868 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.5B |
| IPO Year | 2012 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SMG | KNSA |
|---|---|---|
| Price | $61.60 | $54.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $73.00 | $60.86 |
| AVG Volume (30 Days) | ★ 911.7K | 795.8K |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 4.23% | N/A |
| EPS Growth | ★ 504.92 | 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | ★ $3,016,500,000.00 | $677,564,000.00 |
| Revenue This Year | N/A | $37.48 |
| Revenue Next Year | $2.63 | $17.87 |
| P/E Ratio | ★ N/A | $198.13 |
| Revenue Growth | 6.17 | ★ 60.09 |
| 52 Week Low | $52.00 | $25.71 |
| 52 Week High | $72.35 | $54.31 |
Technical Indicators
Market Signals| Indicator | SMG | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 44.59 | 71.26 |
| Support Level | $58.74 | $40.67 |
| Resistance Level | $65.38 | N/A |
| Average True Range (ATR) | 2.86 | 2.27 |
| MACD | -0.16 | 1.15 |
| Stochastic Oscillator | 23.67 | 96.82 |
Price Performance
Historical ComparisonAbout SMG Scotts Miracle-Gro Company (The)
Scotts Miracle-Gro is the largest purveyor of home lawn and gardening products in the US. The company sells a broad range of lawncare products, including grass seed, fertilizer, and lawn-related weed, animal, and disease control. US consumer typically generates the vast majority of companywide revenue and profits. Its lawncare and gardening products are well-recognized brands in the US, including Scotts, Miracle-Gro, Roundup, Ortho, and Tomcat.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.